Methods for Modulating Skin Inflammation

Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

1 .- 18 . (canceled) 
     
     
         19 . A method for the suppression or amelioration of skin inflammation in a subject having an inflammatory disease of the integument, the method comprising the step of administering to the subject about 0.1-1000 μg/cm 2  applied area an effective amount of Amnion-derived Cellular Cytokine Solution (ACCS) such that the skin inflammation is suppressed or ameliorated. 
     
     
         20 . The method of  claim 19  wherein the inflammatory disease of the integument is selected from the group consisting of psoriasis and atopic dermatitis. 
     
     
         21 . The method of  claim 19  wherein the ACCS is co-administered with one or more active agents. 
     
     
         22 . The method of  claim 21  wherein the one or more active agents is selected from the group consisting of a corticosteroid, cyclosporine, tacrolimus, sirolimus, methotrexate, azathiopine, mercatopurine, a cytotoxic antibiotic, a polyclonal antibody, a monoclonal antibody, an interferon, opioid, a TNF binding protein, mycophenolate, FTY720 and other cells types. 
     
     
         23 . The method of  claim 22  wherein the monoclonal antibody is selected from the group consisting of an anti-T-cell receptor (CD23) and an anti-IL2 receptor (CD25) antibody.